September 07, 2017
Kite Pharma Inc. didn't ask for enough money from Gilead Sciences Inc. when it agreed to be bought last month, according to a proposed class of investors who alleged in a California federal suit Thursday that the biopharmaceutical company is worth more than the pitched $12 billion.